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Abstract: Medullary thyroid carcinoma (MTC) is a rare calcitonin producing neuroendocrine tumour that originates from 
the parafollicular C-cells of the thyroid gland. The RET proto-oncogene encodes the RET receptor tyrosine kinase, with 
consequently essential roles in cell survival, differentiation and proliferation. Somatic or germline mutations of the RET 
gene play an important role in this neoplasm in development of sporadic and familial forms, respectively. Genetic 
diagnosis has an important role in differentiating sporadic from familiar MTC. Furthermore, depending on the location of 
the mutation, patients can be classified into risk classes. Therefore, genetic screening of the RET gene plays a critical role 
not only in diagnosis but also in assessing the prognosis and course of MTC. 
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INTRODUCTION 
  Medullary Thyroid Carcinoma (MTC) is a rare 
neuroendocrine tumour arising from the calcitonin (Ct) 
producing parafollicular C cells of the thyroid. Serum Ct 
levels are elevated in C cell diseases, making it a sensitive 
biochemical marker for MTC. Recently a systematic review 
of autopsies has demonstrated that a small number of people 
in the general population have an occult MTC with a 
prevalence of 0.14% reaching to 0.42% when associated to 
Ct staining. MTC size was less than one centimetre, 
occurring prevalently in patients older than 60 years, with no 
gender difference [1]. 
  MTC accounts for approximately 5-8% of all thyroid 
cancer. Clinically, MTC is mainly sporadic (70-80%), but 
hereditary pattern is present in 20-30% of cases, transmitted 
as an autosomal dominant trait [2].  
  Sporadic form of MTC is observed in 60-70 years old 
patients with a palpable thyroid nodule indistinguishable 
from any other thyroid nodule. Neck lymph node metastases 
are detected in at least 50% of patients and may reveal the 
disease. Metastases outside the neck, in liver, lungs or bones, 
are initially present in 10 - 20% of the cases. 
  Hereditary MTC may be part of “multiple endocrine 
neoplasia type 2” (MEN2) and is divided into three clinical 
forms:  
A)  MEN2a is characterised by the presence of MTC in 
combination with pheochromocytoma and/or 
hyperpathy-roidism. Cutaneous lichen amyloidosis 
has been observed in some families [3] and 
Hirschsprung’s disease observed in a few families 
with MEN2a [4]. The typical onset of this   
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condition is in the third or fourth decade of life. 
Nearly the 100% of gene carriers will develop MTC, 
but this depends on the mutation [5]. The risk of 
developing unilateral or bilateral pheochromocytoma 
is as high as 57% (both for germline mutations of 
codon 918 and 634), and 15– 30% of codon 634 
mutations carriers will develop hyperpathyroidism 
[5,6]. 
B)  MEN2b in which MTC is accompanied by 
pheochromocytoma, multiple mucosal neuromas and 
marfanoid habitus. MEN2b is the most rare and 
aggressive form of MEN 2 based on its development 
of MTC earlier in life, usually before the age of 5-10 
years. It is frequently associated with extension 
beyond the thyroid capsule, with lymph node and 
distant metastasis at the time of diagnosis [7]. Patients 
also have chronic constipation and colonic cramping 
due to the presence of megacolon disorder. More than 
50% of cases are “de novo” germline mutations [8]. 
The higher mortality rate of MEN 2B reflects its more 
advanced stage at presentation, rather than the tumour 
behaviour once established [9-11].  
C)  FMTC (Familiar Medullary Thyroid Carcinoma) 
occurs when MTC is the only clinical feature. 
Clinical presentation of cancer is at a later age and a 
relatively more favourable prognosis. The most rigid 
definition is multigenerational transmission of MTC 
in which no family member has pheochromocytoma 
or hyperpathyroidism; a less rigid definition is the 
presence of MTC in four affected family members 
without other manifestations of MEN 2A [12]. 
  Histology is peculiar in hereditary MTC; C-cells 
hyperplasia is always associated with hereditary MTC with 
bilaterality and multicentricity as a consequence when the 
patients over 5-years old, carry the codon 918 or codon 634 
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single tumour confined to one thyroid lobe, except for a 5-
9% of patients [13]. Tumour metastasizes early to 
paratracheal and lateral cervical lymph nodes; lymph nodes 
metastasis are found in 20-30% of patients with MTC < 1 cm 
in diameter, in 50% with tumour > 2 < 4 cm and in up 90% 
of the patients with more than 4 cm in diameter or 
infiltrating surround thyroid tissues. The prognosis of MTC 
is intermedia between well differentiate thyroid carcinomas 
and anaplastic thyroid cancer. It is worse respect to papillary 
and follicular thyroid cancer and better to anaplastic thyroid 
cancer. Therefore, an early diagnosis is fundamental for a 
good prognosis in these patients [14-16]. 
  Genetic abnormalities are present in MTC, and hereditary 
forms are characterised by germline mutations while 
sporadic MTC showed somatic alterations in 40-60% of 
patients. 
RET PROTONCOGENE 
  The “REarrangement during Transfection” (RET) proto-
oncogene, which is primarily expressed in neuronal crest-
derived and urogenital progenitor cells, is required for the 
development of enteric nervous system, kidney 
morphogenesis and differentiation of spermatogonia [17]. 
  The predisposing gene for hereditary MTC was RET 
proto-oncogene localized to centromeric chromosome 10 by 
linkage analysis in 1987, and germline mutations of the RET 
proto-oncogene were identified in 1993 in MEN2A, MEN2B 
and FMTC [18-20].  
  The human RET gene maps on 10q11.2 and is composed 
of 21 exons with a size of about 55 kb [21, 22]. The RET 
proto-oncogene encodes a tyrosin kinase transmembrane 
receptor which is mainly expressed in neural crest-derived 
cell lineages as parafollicular C cells, adrenal medullary cells 
and parathyroid cells. RET receptor plays a pivotal role in 
regulating cell proliferation, migration, and differentiation. 
The plasma membrane tyrosine kinase receptor is 
characterised by three different domains: i) the extracellular 
domain, ii) the transmembrane domain, and iii) the 
intracellular tyrosine kinase domain. The extracellular 
domain contains four Ca2-dependent cell adhesion 
(cadherin)-like domains that are thought to induce and 
stabilize conformational changes for interaction with ligands 
and co-receptors, and a cysteine-rich region responsible for 
the tertiary structure and ligand-induced dimerization of two 
RET molecules formation of dimers [23, 24]. The 
transmembrane domain ensures the close proximity of the 
RET proto-oncogene monomers through non-covalent 
receptor-receptor interactions [25]. The intracellular region 
comprises a juxta-membrane domain, and two tyrosine 
kinase subdomains (TK1 and TK2) that are involved in the 
activation of numerous intracellular signal transduction 
pathways. 
  Alternate splicing of RET produces three isoforms with 
either 9, 43, or 51 amino acids at the C terminus, referred to 
as RET9, RET43, or RET51 (Fig. 1). 
  Under normal conditions RET can be activated by a 
complex of coreceptors and ligands. These belong to two 
groups of proteins: the GDNF (Glial cell line-Derived 
Neurotrophic Factor) and the glycosylphosphatidylinositol-
anchored GDNF- family   receptor. Binding of the ligand to 
the extracellular domain of the RET tyrosin kinase induces 
receptor dimerization and autophosphorylation, creating 
intracellular binding sites for signalling proteins with the 
subsequent activation of multiple signalling pathways. In 
fact, autophosphorylation at specific cytoplasmatic Tyr 
residues provides the docking site for several 
adaptor/signalling proteins and is a requirement for the 
receptor signal transduction. 
  Alterations of the RET proto-oncogene are involved in 
the development of different human diseases. “Gain of 
function” mutations, leading to aberrant activation of RET, 
are specific oncogenic events in the thyroid gland. RET 
oncoproteins expressed in the thyroid carcinomas are 
Fig. (1). Shows the RET receptor consists of 3 parts. Grey 
extracellular cadherin-like region and the region rich in cysteine. 
Black transmembrane region and Red intracytoplasmic region with 
tyrosine kinase activity. They are also representing the three 
isoforms (RET9, RET43 and RET51).
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characterised by constitutive ligand-independent tyrosine 
kinase activity necessary for their transformation ability [26]. 
RET ACTIVATION IN MTC 
  Mutated RET plays a very significant role in the 
development of human neuroendocrine tumours and tumour 
syndromes. The activation of oncogenic RET depends on the 
location of the amino acid change. Normally, cysteine 
residues are involved in intramolecular disulfide bonds in 
wild-type RET. Mutations in the extracellular cysteine-rich 
domain convert a cysteine residue into a noncysteine residue. 
These mutations leave an unpaired cysteine residue in a RET 
monomer to form an aberrant intermolecular disulfide bond 
with another mutated monomer. The two mutated RET 
molecules are constitutively dimerized and activated. 
Mutations in the intracellular tyrosine kinase domain activate 
tyrosines in the kinase domain and alter its substrate 
specificity due to structural changes of the binding pocket of 
the tyrosine kinase domain. They lead to aberrant 
phosphorylation of substrates preferred by cytoplasmic 
tyrosine kinases [27]. Consequently, the mutated RET no 
longer needs dimerization to become active [28]. 
  MTCs are characterised by activating mutations of RET 
proto-oncogene which occur prevalently as point alteration 
of codons. In 98% of MEN 2a families, a germ-line 
activating RET mutation can be detected [5]. Germline RET 
mutations indicate hereditary MTC and determine the 
lifetime risk for developing MTC, which is nearly 100% for 
RET mutation carriers. A high prevalence of “de novo” RET 
mutations (over 50%) has been identified in MEN 2b 
patients, and to a lesser extent in MEN 2a⁄FMTC patients. 
Also, germ-line RET mutations are frequently detected in 
apparently sporadic MTC patients, indicating the importance 
of genetic testing in all MTC patients, even without a clear 
indication for hereditary disease. 
  Somatic RET mutations can be detected in tumour tissue 
of 40-60% of sporadic MTC patients. The contribution to 
tumour development of somatic RET mutations in MTC 
pathogenesis is unclear. Somatic RET mutations are not 
consistently distributed within primary tumours and 
metastases, indicating that the mutation can occur during 
progression of the tumour or that MTC is a disease of 
polyclonal origin [29]. Probably in these cases, somatic RET 
mutations merely contribute to the disease phenotype instead 
of causing it. 
 Fig.  (2) shows the most frequent germlines of somatic 
mutations. 
GERMLINE MUTATIONS 
  In 98% of MEN2a patients, mutations occur in one of the 
five cysteines in the extracellular cysteine-rich domain of 
RET and are localized in exons 10-11 of RET oncogene. The 
majority of MEN2b patients, about 95% of cases, carry the 
mutations in the intracellular tyrosin-kinase domain of RET 
localized in exon 16. In FMTC, mutations affect either 
extracellular cystein or intracellular domain of RET 
concerning all previous exons [30-32].
  Extracellular cysteine RET mutations exert constitutive 
kinase activity consequence which is independent from 
ligand. In the cases of mutation M918T, constitutive RET 
activation probably results from disruption of an auto-
inhibited head-to-tail RET tyrosine kinase homodimer [33]. 
  Some studies have found an overlap between RET 
mutations and clinical subtypes of MEN2, identifying the 
genotype-phenotype very substantial [5, 30, 34]. In 
particular, hyperparathyroidism in MEN2a is associated with 
high frequency, with the mutation 634, especially in the Cys-
Arg substitution, less frequently with mutations in codons 
609, 611, 618, 620, 790, 791. Moreover, the mutation of 
codon 918 in exon 16 is associated with the MEN2b present 
in 95% of cases and is usually a “de novo” mutation that 
appeared for the first time in sick patients and not inherited 
by their healthy parents. 
  In both ItaMEN [35] and the German series [36], the 
majority of RET families harboured codon 634 mutations 
(37% of Italian vs. 41% of German RET families). Codon 
804 and 891 mutations affected some 22% and 10% of 
Italian vs. 6% and 2% of German RET families. Conversely, 
codon 790 and 791 mutations were more common in 
German than Italian RET families (12% vs. 3% and 7% vs.
<1%). 
  Moreover, a high prevalence of several mutations 
affecting non-cysteine codons, some of which were never 
reported before as we demonstrated in a family of FMTC 
with a mutation of Cys 515 in exon 8 which induced gain of 
function of RET gene [37]. The different ethnic origins of 
the patients and the particular attention given to analysing 
apparently sporadic MTC for RET germlines mutations may 
explain these Italian data.
  The correlation between genotype and phenotype is not 
only for the clinical but also the age of onset of MTC and its 
aggressiveness. Guidelines in 2001 have suggested to 
consider the age of surgery according to three risk categories 
according to RET mutation (levels 1, 2, 3) [5]. The 2009 
American Thyroid Association (ATA) guidelines established 
a four-level risk categorization (classes A, B, C, D) 
recognizing the most aggressive course of the 634 mutation 
within level 2 [38]. For patients with mutation at codon 918 
(MEN 2b), surgery is recommended during the first year of 
life, and as soon as possible (level 3 in the past, D currently). 
Regarding mutations in exons 10 and 11, prophylactic 
surgery is proposed before the age of 5 (level 2, ATA class 
C). Finally, for mutations in exons 13, 14, and 15, 
prophylactic surgery may be delayed beyond the age of 5, in 
the absence of any evidence of C cell disease (level 1, A) [4, 
37]. However, these recommendations were mainly based on 
the age-related tumour, node metastasis (TNM) status rather 
than long-term follow-up data. Surgery should include a total 
thyroidectomy, but timing and extent of lymph node 
dissection are still a matter of debate, being currently based 
on the germline mutation, the age at surgery, and on any 
evidence of disease, including neck ultrasonography and 
serum calcitonin (CT) levels [38-41].
  In a German Austrian study authors have demonstrated 
that patients with rare mutations at codons 790, 791 and 804 
showed differ onset and outcome. In particular, there is a 
significant difference in MTC development with less 
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additional endocrinopathies in carriers of RET  codon 791 
mutations compared with carriers of codons 790 and 804 
mutations [42].
  Recently a French study has demonstrated that the 
prognostic factor of disease free survival after surgery in 
young patients with RET germline mutation is best predicted 
by TNM staging and preoperative basal CT level below 30 
pg/ml. Basal CT, class D genotype, and age constitute key 
determinants to decide preoperatively timely surgery [43]. 
  Moreover, genetic screening of germline RET mutations 
permits to identify unsuspected FMTC in apparently 
sporadic MTC patients. Therefore, RET genetic screening of 
patients with apparently sporadic MTC represents a major 
tool for the preclinical diagnosis and early treatment of 
unsuspected affected family members and allows the 
identification of a relevant percentage of hidden FMTC. 
  Given the high chance of a RET gene carrier developing 
MTC at some point during their life, these patients should be 
offered prophylactic thyroidectomy. In cases of MEN 
2a/FMTC mutations of ATA level C risk, prophylactic total 
thyroidectomy should be carried out before 5 years of age 
[38]. In patients with RET mutations of ATA level A and B 
risk, prophylactic thyroidectomy may be delayed beyond the 
first 5 years in the setting of a normal basal and/or stimulated 
serum CT and normal annual cervical ultrasound starting at 5 
years of age [38]. Prophylactic level VI central compartment 
neck dissection may not be necessary in patients with MEN 
2a/FMTC who undergo prophylactic thyroidectomy within 
their first 3-5 years of life unless there is clinical or 
radiological evidence of lymph node metastases, thyroid 
nodules >5 mm in size or a serum basal CT >40 pg/ml in a 
child >6 months old [38]. Children with MEN 2b (ATA level 
D risk) should have thyroidectomy as soon as possible, 
preferably within the first year of life. Prophylactic level VI 
neck dissection may not be necessary in patients with MEN 
2b, unless there is clinical or radiological evidence of lymph 
node metastases [38]. In RET-mutation-positive patients, 
screening for pheochromocytoma, including annual plasma 
metanephrines and normetanephrines, or 24-h urine 
collection for metanephrines and normetanephrines, begins 
by 8 years of age in carriers of the RET mutation associated 
with MEN 2b and codons 630 and 634, and by 20 years of 
Fig. (2). Shows the RET receptor, the gene with its exons and the most common mutations in hereditary and sporadic MTC.
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age in carriers of other MEN 2a RET mutations. Patients 
with RET mutation associated with FMTC alone should be 
screened periodically from 20 years of age. Abdominal 
imaging is not indicated in the absence of symptoms or 
biochemical data [38]. Screening for hyperparathyroidism 
should be carried out with the same interval by measuring 
serum calcium and parathyroid hormone. 
SOMATIC MUTATIONS 
  Somatic mutations are demonstrated in 40 to 60% of 
sporadic MTCs. They occur in the tyrosine kinase domain 
and in cysteine rich domain of RET gene. Mutations located 
in the intracellular region represent approximately one-third 
of all sporadic MTC and only a few mutations or deletion 
have been reported in the extracellular cystein-rich domain 
[44-46]. The most common mutation is M918T, although 
many other codons could show mutations (Fig. 2) [29, 47- 
49].  
  In few cases of sporadic MTC a deletion of codons 
Glu632 and Leu633 was identified. These mutations activate 
more effectively the RET gene in comparison to the Cys 
634Arg missense mutation and they induce stable dimers 
formation in the absence of ligand [50]. 
  More aggressive sporadic MTC showed the M918T RET 
mutation in about 30-50% [51]. It has been demonstrated 
that the presence of a somatic RET mutation (M918T) 
correlates with stage of the disease, a high probability to 
have persistence of the disease after total thyroidectomy, 
increased chance of recurrence and metastatic potential, and 
a reduced survival. This indicates that the presence of 
somatic RET mutations may function as a prognostic 
biomarker [52]. 
  Moreover, correlation was identified between the 
presence of somatic mutations with more advanced 
pathological TNM stage [53]. 
RET PROTO-ONCOGENE POLYMORPHISMS 
  Single nucleotide polymorphisms (SNPs) are allelic 
variants of a gene that occur when one nucleotide is replaced 
without alteration of functional activity of the encoded 
protein. SNPs have been reported to function as genetic 
modifiers of RET protooncogene mutations, resulting in the 
expression of MTC and PTC. Specifically, SNP G691S in 
exon 11 and SNP S904S in exon 15 are believed to be 
responsible for the development of MTC in patients with 
germline RET proto-oncogene mutations. It also has been 
reported that SNPs G691S and S904S appear to influence the 
age of onset of MTC in patients with MEN 2A syndrome. 
Several reports have shown that patients homozygous for 
these polymorphisms were, on average, diagnosed with 
MTC 10 years earlier than patients with MEN 2A bearing 
heterozygous or wild-type haplotype [54]. Siqueira and 
coworkers recently demonstrated higher frequencies of RET 
polymorphism (L769L, S836S, S904S, G691S) in hereditary 
and sporadic MTC (102 and 81 patients respectively) than 
controls. They also detected that individuals harbouring the 
S836S variant were younger and showed a higher percentage 
of lymph node and distant metastases [55]. Sromek et al.
compared the frequency of three polymorphic changes in the 
RET proto-oncogene (L769L, S836S and S904S) between 
patients with MTC and the general population. In their paper 
they evidenced the predisposition role of SNP L769L in the 
developing of sporadic MTC and also in the lowering the age 
of onset of MTC in carriers of the homozygous SNP L769L. 
[56]. At least, Pasquali and his colleagues recently reported a 
new SNP, V109G. They detected that, in sporadic MTC, the 
V109G polymorphism correlates with a more favourable 
disease progression than the wild-type allele [57]. 
RAS MUTATIONS IN MTC 
  Mutations of RAS occur with variably frequency in all 
types of thyroid follicular cell-derived tumours (papillary 
and follicular thyroid cancer) and discordant data have been 
published in MTC. The RAS genes (H-RAS, K-RAS, and N-
RAS) encode highly related G-proteins that are located at the 
inner surface of the cell membrane and play a central role in 
the intracellular transduction of signals arising from cell 
membrane receptors tyrosine kinase and G-protein-coupled 
receptors. In its inactive state, RAS protein is bound to 
guanosine diphosphate (GDP). Upon activation, it releases 
GDP and binds guanosine triphosphate (GTP), activating the 
MAPK and other signalling pathway, such as PI3K/AKT. 
Normally, the activated RAS-GTP protein becomes quickly 
inactive due to its intrinsic guanosine triphosphatase 
(GTPase) activity and the action of cytoplasmic GTPase-
activating proteins, which catalyse the conversion of the 
active GTP form to the inactive GDP-bound form. In many 
human neoplasms, point mutations occur in the discrete 
domains of the RAS gene, which result in either an increased 
affinity for GTP (mutations in codons 12 and 13) or 
inactivation of the autocatalytic GTPase function (mutations 
in codon 61). As a result, the mutant protein becomes 
permanently switched in the active position and 
constitutively actives its downstream signalling pathways 
[58]. Absence of H-RAS and K-RAS, as well N-RAS 
mutations in sporadic MTC was described in early reports 
except Okazaki et al. who identified a H-RAS mutation in 
one out of 10 sporadic MTC [59]. More recently, somatic 
mutations of H-RAS and K-RAS genes have been identified 
in sporadic MTC without RET mutation by Muora and 
coworkers and no mutations of N-RAS were detected. They 
hypothesise that activation of the protoncogenes RAS and 
RET is likely to represent alternative genetic events in MTC 
tumorigenesis [60]. Similar results were found by Goutas et
al. They detected mutation of codon 12 of K-RAS in 18 
(40.9%) out of 44 sporadic MTC [61]. 
RET AS THERAPEUTIC TARGET IN MTC 
  Several small-molecule tyrosine kinase (TK) inhibitors 
directed towards RET kinase have been tested in preclinical 
and clinical studies and have been proven to be effective in 
the treatment of several neoplastic disease, including thyroid 
cancers [58]. After treatment with TK inhibitors in a large 
number of patients with thyroid cancers (25-81%) a stable 
disease state can be established, and some patients even 
show a partial response (2-33%). Verbeek and coworkers set 
out to compare the efficiency of four recently developed TK 
inhibitors, XL184, Vandetanib, Sunitinib and Axitinib, using 
three cell lines: the first derived from sporadic MTC 
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metastatic sporadic MTC expressing a M918T RET 
mutation. They detected that all four TK inhibitors are 
capable of reducing cell proliferation, however, XL184 was 
found to be the most efficient inhibitor for MEN2A derived 
cells lines, whereas vandetanib proved to be the most potent 
inhibitor for MEN2B [62]. Recently has been evaluated the 
combination of a multikinase inhibitor (Sorafenib) with a 
farnesyltransferase inhibitor (Tipifarnib) in the treatment of 
thyroid tumours. Sorafenib is a potent oral multikinase 
inhibitor of Raf-1, platelet-derived growth factor receptor, 
RET, KIT, and vascular endothelial growth factor receptor-2. 
Tipifarnib is a selective oral farnesyltransferase inhibitor, 
inducing antiproliferative effects against various human 
tumour cell lines. The authors tested the hypothesis that 
more clinical activity should be achieved by using the 
combination of sorafenib and tipifarnib, given the 
importance of Ras/Raf/MAPK kinase/ERK and RET kinase 
in thyroid malignancies. At the end of the study, among 
patients with MTC, they evidenced a 38% of partial response 
and a 31% of stable disease at 6 months. Therefore, they 
have considered useful association of sorafenib and 
tipifarnib in the treatment of aggressive MTC [63]. 
CONCLUSIONS 
  RET screening for detection of genetic mutations is 
essential for a correct approach in the management of MTC. 
All subjects with a diagnosis of MTC, even without a family 
history of MEN2 should be subjected to genetic analysis of 
RET, in order to confirm or exclude the inheritance of the 
disease. Indeed, as previously reported, a rate between 5-
10% of sporadic forms had RET germline mutation. RET 
screening is also essential to assess first-degree relatives of 
proband to determine their possible carrier status for the 
relationship between type of mutation and the aggressiveness 
of disease, and the correct timing of prophylactic 
thyroidectomy.
  In sporadic form of MTC also the identification of 
somatic RET mutation has a prognostic value making it 
possible to select individuals who require a more careful 
follow-up. In fact, the presence of somatic mutations in 
specific codons of RET gene correlates with greater 
aggressiveness and worse prognosis. Therefore, the search 
for somatic mutations plays an important role in the clinical 
course and follow-up of patients with sporadic MTC. 
  Therefore, screening of the RET gene today is a 
milestone in the management of all patients with newly 
diagnosed MTC and all the family of a patient with known 
RET germline mutation. 
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